To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
All releases
English
Initiator Pharma completes dosing in Phase 2a trial with IP2018
Initiator Pharma A/S, a clinical-stage biotech company, today announced that it has completed dosing all 24 patients for its Phase 2a clinical trial with IP2018. Draft results are expected end of Q2 2023, as previously communicated.
Initiator Pharma has decided not to exercise the option for an undisclosed pain asset
Initiator Pharma A/S, a clinical-stage pharma company, announced today its decision not to exercise the exclusive option agreement for a Phase II/III ready pharmaceutical asset. With this decision the company reiterates previous statement that its current cash position will be sufficient to fund all planned and committed activities through 2024.
Initiator Pharma: Financial calendar for 2023
Initiator Pharma A/S (“Initiator” or the “Company”) announces that the board of directors expects to publish financial reports according to the following schedule:
Initiator Pharma ready to start Phase I pharmacokinetics study for new IP2015 formulations
Initiator Pharma A/S, a clinical-stage pharma company, announced today that it will initiate a Phase I pharmacokinetic study in healthy subects evaluating new oral solid dosage forms enabling a bridging between previous data sets into new future clinical studies for IP2015.
Initiator Pharma provides an update on its clinical programs
Initiator Pharma A/S, a clinical-stage pharma company, announced today an update on its ongoing and planned clinical studies.
Result of incentive program “LTI2022” in Initiator Pharma A/S
The AGM held on May 24, 2022 approved two long-term incentive programs (“LTI2022”), one for Management and leading employees and one for board members.LTI2022 for Management and leading…
Initiator Pharma reports the final analysis of positive efficacy data from the IPTN2021 program Phase I study
Initiator Pharma A/S, a clinical-stage pharma company, announced today that the final dataset and study- report analysis have been obtained in the IPTN2021 program. The IPTN2021 program is a clinical Phase I study in healthy subjects dosed with the drug IP2015 and challenged with a pain-inducing ingredient (capsaicin). The final analysis confirms the statistically significant effects on pain measures that were observed in the analysis of the first data read-out from the study presented in May 2022.